AU Patent

AU2024275269A1 — Methods of treating vitiligo with upadacitinib

Assigned to AbbVie Inc · Expires 2025-11-06 · 1y expired

What this patent protects

The present disclosure is directed to methods for treating vitiligo using the selective JAK1 inhibitor upadacitinib.

USPTO Abstract

The present disclosure is directed to methods for treating vitiligo using the selective JAK1 inhibitor upadacitinib.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024275269A1
Jurisdiction
AU
Classification
—
Expires
2025-11-06
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.